IDH3A and glioma: Among these markers, isocitrate dehydrogenases (IDHs) play a central role in glioma characterization and have become a routine part of histopathological diagnosis, drug sensitivity assessment, and prognosis evaluation as outlined in the WHO CNS5 2021 guidelines [39].